# Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin

> **NCT04204837** · PHASE2 · RECRUITING · sponsor: **Salzburger Landeskliniken** · enrollment: 61 (estimated)

## Conditions studied

- Squamous Cell Carcinoma of the Skin

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Nivolumab plus Relatlimab

## Key facts

- **NCT ID:** NCT04204837
- **Lead sponsor:** Salzburger Landeskliniken
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2017-03-06
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2024-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04204837

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04204837, "Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04204837. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*